Загрузка...
A review of omalizumab for the management of severe asthma
Despite the expansion of the understanding in asthma pathophysiology and the continual advances in disease management, a small subgroup of patients remain partially controlled or refractory to standard treatments. Upon the identification of immunoglobulin E and other inflammatory mediators, investig...
Сохранить в:
| Опубликовано в: : | Drug Des Devel Ther |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4970638/ https://ncbi.nlm.nih.gov/pubmed/27528798 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S112208 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|